Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

25.90 -0.05 (-0.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Harmony Biosciences's Earnings: A Preview
 
Via Benzinga
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock
Harmony Biosciences Holdings (NASDAQ:HRMY) is a strong affordable growth stock with high growth, solid profitability, and attractive valuation. Learn why it stands out in the pharmaceutical sector. 
Via Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock Candidate
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock Candidate 
Via Chartmill
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Uncover the potential of HARMONY BIOSCIENCES HOLDINGS, an undervalued stock. NASDAQ:HRMY maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing.
Discover HARMONY BIOSCIENCES HOLDINGS, an undervalued growth gem. NASDAQ:HRMY is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
Demystifying Harmony Biosciences Hldgs: Insights From 11 Analyst Reviews
 
Via Benzinga
Earnings Scheduled For February 25, 2025
 
Via Benzinga
Demystifying Harmony Biosciences: Insights From 5 Analyst Reviews
 
Via Benzinga
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
 
Via Benzinga
Breaking Down Harmony Biosciences Hldgs: 13 Analysts Share Their Views
 
Via Benzinga
Friday's pre-market session: top gainers and losers
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
In the world of growth stocks, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) shines as a value proposition.
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY): a strong growth stock preparing for the next leg up?.
Based on a technical and fundamental analysis of NASDAQ:HRMY we can say: HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
NASDAQ:HRMY is not too expensive for the growth it is showing.
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing. 
Via Chartmill
Analyst Expectations For Harmony Biosciences's Future
 
Via Benzinga
Expert Outlook: Harmony Biosciences Hldgs Through The Eyes Of 11 Analysts
 
Via Benzinga
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), a growth stock which is not overvalued.
Discover HARMONY BIOSCIENCES HOLDINGS, an undervalued growth gem. NASDAQ:HRMY is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag.
When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Harmony Biosciences (HRMY) Q4 2024 Earnings Call Transcript
HRMY earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a Phase 3 trial planned for late 2025. 
Via Benzinga
Harmony Biosciences Crashes On Surprise Rejection For Bread-And-Butter Drug
The agency rejected the drug in the application filing stage, which is earlier than usual. 
Via Investor's Business Daily
While growth is established for NASDAQ:HRMY, the stock's valuation remains reasonable.
HARMONY BIOSCIENCES HOLDINGS could be undervalued. NASDAQ:HRMY is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill
NASDAQ:HRMY, a growth stock which is not overvalued.
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
Friday's after hours session: top gainers and losers
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Some companies saw their shares skyrocket on preliminary reports, but others took hits. 
Via Investor's Business Daily
Investors should take note of NASDAQ:HRMY, a growth stock that remains attractively priced.
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Don't overlook NASDAQ:HRMY—it's a hidden gem with strong fundamentals and an attractive price tag.
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), an undervalued stock with good fundamentals. 
Via Chartmill
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders. 
Via Benzinga
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript
HRMY earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.